Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.

Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS, Schoenfeld JD, Ott PA.

J Immunother Cancer. 2019 Mar 29;7(1):89. doi: 10.1186/s40425-019-0512-5.

2.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.

PMID:
30388455
3.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM.

Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27.

4.

Possible neurotoxicity of the anesthetic propofol: evidence for the inhibition of complex II of the respiratory chain in area CA3 of rat hippocampal slices.

Berndt N, Rösner J, Haq RU, Kann O, Kovács R, Holzhütter HG, Spies C, Liotta A.

Arch Toxicol. 2018 Oct;92(10):3191-3205. doi: 10.1007/s00204-018-2295-8. Epub 2018 Aug 24.

5.

Trapping Cancers as They Adapt to Survive.

Haq R.

Cancer Discov. 2017 Nov;7(11):1216-1217. doi: 10.1158/2159-8290.CD-17-0976.

6.

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.

Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue H, Davis M, Gargano ME, Kelley KM, Carroll RS, Kaiser UB, Min L.

Cancer Immunol Res. 2017 Dec;5(12):1133-1140. doi: 10.1158/2326-6066.CIR-17-0208. Epub 2017 Oct 27.

7.

Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.

Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI.

Cancer Immunol Res. 2017 May;5(5):357-362. doi: 10.1158/2326-6066.CIR-16-0287. Epub 2017 Apr 10.

8.

Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood.

Gee MS, Ghazani AA, Haq R, Wargo JA, Sebas M, Sullivan RJ, Lee H, Weissleder R.

Nanomedicine. 2017 Apr;13(3):821-828. doi: 10.1016/j.nano.2016.12.006. Epub 2016 Dec 18.

9.

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.

Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J, Rosengren F, Holm K, Aine M, Jirström K, Borg Å, Busch C, Geisler J, Lønning PE, Ringnér M, Howlin J, Fisher DE, Jönsson G.

J Invest Dermatol. 2015 Jul;135(7):1820-1828. doi: 10.1038/jid.2015.61. Epub 2015 Feb 23.

10.

Clindamycin 1% Nano-emulsion Gel Formulation for the Treatment of Acne Vulgaris: Results of a Randomized, Active Controlled, Multicentre, Phase IV Clinical Trial.

Bhavsar B, Choksi B, Sanmukhani J, Dogra A, Haq R, Mehta S, Mukherjee S, Subramanian V, Sheikh S, Mittal R.

J Clin Diagn Res. 2014 Aug;8(8):YC05-9. doi: 10.7860/JCDR/2014/9111.4769. Epub 2014 Aug 20.

11.

A Small Molecule Inhibitor of the MITF Molecular Pathway.

Faloon PW, Bennion M, Weiner WS, Smith RA, Wurst J, Weiwer M, Hartland C, Mosher CM, Johnston S, Porubsky P, Neuenswander B, Dandapani S, Munoz B, Schoenen FJ, Metkar S, Haq R, Fisher DE, Aubé J, Palmer M, Schreiber SL.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 13 [updated 2014 Sep 18].

12.

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ.

PLoS One. 2014 Jul 1;9(7):e101286. doi: 10.1371/journal.pone.0101286. eCollection 2014.

13.

The melanoma metastasis X-factor.

Haq R, Flaherty K.

Pigment Cell Melanoma Res. 2014 Sep;27(5):698. doi: 10.1111/pcmr.12285. Epub 2014 Jul 3. No abstract available.

PMID:
24953382
14.

GABAB receptor dependent modulation of sharp wave-ripple complexes in the rat hippocampus in vitro.

Hollnagel JO, Maslarova A, Haq RU, Heinemann U.

Neurosci Lett. 2014 Jun 27;574:15-20. doi: 10.1016/j.neulet.2014.04.045. Epub 2014 May 4.

PMID:
24796812
15.

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.

Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA.

Cancer Discov. 2014 Jul;4(7):816-27. doi: 10.1158/2159-8290.CD-13-0424. Epub 2014 Apr 25.

16.

Metabolic dysregulation in melanoma: cause or consequence?

Haq R.

Cancer Discov. 2014 Apr;4(4):390-1. doi: 10.1158/2159-8290.CD-14-0173.

17.

Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.

Haq R, Fisher DE, Widlund HR.

Clin Cancer Res. 2014 May 1;20(9):2257-63. doi: 10.1158/1078-0432.CCR-13-0898. Epub 2014 Mar 7. Review.

18.

Improving apoptotic responses to targeted therapy.

Haq R, Fisher DE.

Oncotarget. 2013 Sep;4(9):1331. No abstract available.

19.

Targeting melanoma by small molecules: challenges ahead.

Haq R, Fisher DE.

Pigment Cell Melanoma Res. 2013 Jul;26(4):464-9. doi: 10.1111/pcmr.12109. Epub 2013 May 28. Review.

20.

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR.

Cancer Cell. 2013 Mar 18;23(3):302-15. doi: 10.1016/j.ccr.2013.02.003. Epub 2013 Mar 7.

Supplemental Content

Loading ...
Support Center